Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women between 18 and 70 years old
- People who have been diagnosed with HER2-positive breast cancer (confirmed through a tissue sample) and are planned to receive a specific pre-surgery chemotherapy treatment called T(P)CbHP
- People whose cancer is at a specific stage, classified as T2N0-2M0 (confirm with trial site for what this means in your case)
- People whose blood cell counts are within an acceptable range, showing the bone marrow is working well enough
- People whose liver is functioning within acceptable limits based on blood tests
- People whose kidneys are filtering well enough, measured by a specific blood or urine test
- People whose heart is pumping strongly enough, with a measurement of at least 50% on a heart scan
- People who are able to follow the study schedule without major personal, family, social, or location-related barriers
- People who do not have other health conditions that would put them at serious risk during the trial
- People who have given written agreement to take part in the trial
Who may not be able to join:
- People who have previously had radiotherapy or chemotherapy
- People who are pregnant or currently breastfeeding
- People whose cancer has spread to other parts of the body
- People who have invasive breast cancer in both breasts
- People who are currently receiving other cancer treatments or taking part in another clinical trial
- People who have significant heart, liver, or kidney problems, or other serious physical health issues such as severe infection, high fever, or major fluid or chemical imbalances in the body
- People who have a known allergy or sensitivity to a substance called SonoVue® (a contrast agent used in ultrasound scans)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yiding Chen, The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU)
Phone: +86-13616555799
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pathological Complete Response rate; Tumor Pathological Complete Response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.